Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: Implications for selection of clinical dose

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 5, 2011, Pages 726-734

  Dairaghi, D J ^a   Zhang, P ^a   Wang, Y ^a   Seitz, L C ^a   Johnson, D A ^a   Miao, S ^a   Ertl, L S ^a   Zeng, Y ^a   Powers, J P ^a   Pennell, A M ^a   Bekker, P ^a   Schall, T J ^a   Jaen, J C ^a  

^a ChemoCentryx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCX 354; CHEMOKINE RECEPTOR CCR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CP 481715; IMMUNOMODULATING AGENT; MLN 3897; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EVALUATION; HUMAN; HUMAN EXPERIMENT; INFLAMMATORY INFILTRATE; LEUKOCYTE; MONOCYTE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MONOCYTES; PROTEIN BINDING; QUINOXALINES; RABBITS; RATS; RATS, WISTAR; RECEPTORS, CCR1; YOUNG ADULT;

EID: 79955483382     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.33     Document Type: Article

References (40)

1. Charo, I.F. & Ransohoff, R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006). (Pubitemid 43209108)
2. Viola, A. & Luster, A.D. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48, 171-197 (2008). (Pubitemid 351756361)
3. Gulick, R.M. et al.; MOTIVaTE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429-1441 (2008).
4. Brave, M. et al. FDa review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78, 282-288 (2010).
5. Pease, J.E. & Horuk, R. Chemokine receptor antagonists: part 1. Expert Opin. Ther. Pat. 19, 39-58 (2009).
6. Keshav, S., Johnson, D., Bekker, P. & Schall, T.J. PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate-to-severe Crohn's disease. Gastroenterology 136, A65 (2009).
7. Keshav, S. et al. PROTECT-1 study of intestine-specific chemokine receptor antagonist CCX282-B (TRaFICET-EN) in Crohn's disease. Gut 58, A468 (2009).
8. Haringman, J.J., Kraan, M.C., Smeets, T.J., Zwinderman, K.H. & Tak, P.P. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 715-721 (2003). (Pubitemid 36886404)
9. Gladue, R.P., Brown, M.F. & Zwillich, S.H. CCR1 antagonists: what have we learned from clinical trials. Curr. Top. Med. Chem. 10, 1268-1277 (2010).
10. Zipp, F. et al.; CCR1 antagonist Study Group. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 67, 1880-1883 (2006). (Pubitemid 44900777)
11. Vergunst, C.E. et al. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, Efficacy, Pharmacokinetics, And pharmacodynamics of an oral CCR1 antagonist in a phase IIa, Double-blind, Placebo-controlled, Randomized, Proof-of-concept study. Arthritis Rheum. 60, 3572-3581 (2009).
12. Pease, J.E. & Horuk, R. Chemokine receptor antagonists: part 2. Expert Opin. Ther. Pat. 19, 199-221 (2009).
13. Vergunst, C.E. et al. Modulation of CCR2 in rheumatoid arthritis: a doubleblind, Randomized, Placebo-controlled clinical trial. Arthritis Rheum. 58, 1931-1939 (2008). (Pubitemid 351988084)
14. Haringman, J.J. et al. a randomized controlled trial with an anti-CCL2 (antimonocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54, 2387-2392 (2006). (Pubitemid 44204998)
15. Gerlag, D.M. et al.; ESCaPE Study Group. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, In patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 62, 3154-3160 (2010).
16. Vergunst, C.E., Van de Sande, M.G., Lebre, M.C. & Tak, P.P. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand. J. Rheumatol. 34, 415-425 (2005). (Pubitemid 43062194)
17. Tarrant, T.K. & Patel, D.D. Chemokines and leukocyte trafficking in rheumatoid arthritis. Pathophysiology 13, 1-14 (2006). (Pubitemid 43144576)
18. Haringman, J.J., Smeets, T.J., Reinders-Blankert, P. & Tak, P.P. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, Osteoarthritis, And reactive arthritis. Ann. Rheum. Dis. 65, 294-300 (2006). (Pubitemid 43268215)
19. Szekanecz, Z., Kim, J. & Koch, A.E. Chemokines and chemokine receptors in rheumatoid arthritis. Semin. Immunol. 15, 15-21 (2003). (Pubitemid 36092175)
20. Berahovich, R.D., Miao, Z., Wang, Y., Premack, B., Howard, M.C. & Schall, T.J. Proteolytic activation of alternative CCR1 ligands in inflammation. J. Immunol. 174, 7341-7351 (2005). (Pubitemid 40705704)
21. Tak, P.P. et al. analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 40, 217-225 (1997). (Pubitemid 27114085)
22. Wijbrandts, C.A., Vergunst, C.E., Haringman, J.J., Gerlag, D.M., Smeets, T.J. & Tak, P.P. absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum. 56, 3869-3871 (2007). (Pubitemid 350100720)
23. Tsou, C.L. et al. Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor. J. Exp. Med. 188, 603-608 (1998).
24. Ward, S.G., Bacon, K. & Westwick, J. Chemokines and T lymphocytes: more than an attraction. Immunity 9, 1-11 (1998). (Pubitemid 28361290)
25. Yu, X., Huang, Y., Collin-Osdoby, P. & Osdoby, P. CCR1 chemokines promote the chemotactic recruitment, RaNKL development, And motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J. Bone Miner. Res. 19, 2065-2077 (2004). (Pubitemid 41103422)
26. Vallet, S. et al. MLN3897, A novel CCR1 inhibitor, Impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 110, 3744-3752 (2007). (Pubitemid 350159645)
27. Zhang, P. et al. azaindazole compounds and methods of use. US patent 7,524,845 (2009).
28. Proudfoot, A.E., Power, C.A. & Schwarz, M.K. anti-chemokine small molecule drugs: a promising future? Expert Opin. Investig. Drugs 19, 345-355 (2010).
29. Dairaghi, D.J. et al. a novel CCR1 antagonist CCX354-C for rheumatoid arthritis. Arthritis Rheum. 62, S460 (2010).
30. Dairaghi, D.J. et al. a novel CCR1 antagonist CCX354-C for rheumatoid arthritis. Ann. Rheum. Dis. 69, S214 (2010).
31. Gladue, R.P. et al. CP-481,715, A potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem. 278, 40473-40480 (2003). (Pubitemid 37280857)
32. Cardona, A.E. et al. Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood 112, 256-263 (2008).
33. Aiello, R.J. et al. CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) mice. Atherosclerosis 208, 370-375 (2010).
34. CaRaT-2 Trial Registry Number NCT01242917 (2010).
35. Lu, C., Balani, S.K., Qian, M.G., Prakash, S.R., Ducray, P.S. & Von Moltke, L.L. Quantitative prediction and clinical observation of a CyP3a inhibitor-based drug-drug interactions with MLN3897, A potent C-C chemokine receptor-1 antagonist. J. Pharmacol. Exp. Ther. 332, 562-568 (2010).
36. Clucas, A.T., Shah, A., Zhang, Y.D., Chow, V.F. & Gladue, R.P. Phase I evaluation of the safety, Pharmacokinetics and pharmacodynamics of CP-481,715. Clin. Pharmacokinet. 46, 757-766 (2007). (Pubitemid 47347447)
37. Borregaard, J. et al. Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects. Contact Derm. 59, 212-219 (2008).
38. Neves, C., Chevalier, A. & Billot, P. Solid forms of a chemokine receptor antagonist and methods of use thereof. PCT Pat. appl. WO-2006/066200-a2 (2006).
39. Walters, M.J. et al. Characterization of CCX282-B, An orally bioavailable antagonist of the CCR9 chemokine receptor, For treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 335, 61-69 (2010).
40. Podolin, P.L. et al. a potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J. Immunol. 169, 6435-6444 (2002). (Pubitemid 36903493)